Enclomiphene Citrate Cost in Louisiana 2026

What Does Enclomiphene Citrate Cost in Louisiana Right Now?

The going cash-pay rate for compounded enclomiphene citrate at a licensed 503A pharmacy in Louisiana is approximately $90 per month for a standard 25 mg daily oral capsule supply. That figure sits well below what clomiphene citrate once cost at retail brand pricing, and it is the only practical pricing anchor available because no manufacturer has an FDA-approved enclomiphene product on pharmacy shelves as of early 2026.

To understand why pricing is this narrow, consider the regulatory path. Enclomiphene is the trans-isomer of clomiphene. Repros Therapeutics pursued NDA approval under the brand name Androxal, but the FDA issued a Complete Response Letter in 2013 citing inadequate data on prostate safety and cardiovascular endpoints. [1] Because no approved product exists, the entire commercial market runs through compounding. Compounding pharmacies set their own prices based on raw API cost, overhead, and dispensing fees, which is why $90 is a modal figure rather than a fixed one.

Prices across Louisiana clinics and telehealth providers range from roughly $75 to $110 per month depending on dispensing pharmacy and whether a consultation fee is bundled. Some platforms charge the consultation separately; others fold everything into a subscription. Always ask for an itemized receipt that separates the drug cost from the prescriber visit fee.

Testosterone levels in men with secondary hypogonadism treated with enclomiphene rose from a mean of 237 ng/dL at baseline to 412 ng/dL at 12 weeks in one key trial, without the suppression of sperm parameters seen with exogenous testosterone. [2] That outcome profile is a large part of why demand for enclomiphene has grown despite the absence of an approved product.

How Louisiana Medicaid Treats Enclomiphene Citrate

Louisiana Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The drug carries no FDA approval indication, which places it in the off-label category, and Louisiana's Medicaid formulary does not include compounded medications for this use. [3]

Physicians can submit a prior authorization request arguing medical necessity, but the Louisiana Department of Health has no established pathway for approving compounded SERMs for male hypogonadism under Medicaid. Appeals have a low success rate based on current formulary policy. [4] If you are enrolled in a Louisiana Medicaid managed-care organization such as Aetna Better Health of Louisiana or Healthy Blue Louisiana, the formulary exclusion applies equally across plans because it follows the state's Medicaid Drug Rebate Program rules. [5]

Men who rely on Medicaid and want enclomiphene should expect to pay the full cash price out of pocket. The $90 monthly rate is therefore the floor, not a discounted figure. Assistance programs are limited; see the section on discount options below.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend against the routine use of clomiphene citrate (or its isomers) in men with hypogonadism outside of clinical trials or clearly documented secondary hypogonadism with a desire for fertility preservation." [6] That language matters for coverage appeals because it provides a guideline basis for fertility-sparing intent.

Private Insurance Coverage for Enclomiphene in Louisiana

Private insurance rarely covers enclomiphene citrate in Louisiana. Because the drug has no FDA-approved labeling, most commercial plans classify it as an investigational or unapproved compound and exclude it under their standard pharmacy benefit language. [7]

Plans that might consider coverage include those with broad off-label oncology or endocrine provisions, but male hypogonadism treated with a compounded SERM does not typically trigger those carve-outs. Blue Cross and Blue Shield of Louisiana, Humana, and United Healthcare plans operating in Louisiana all apply medical necessity criteria that reference FDA approval status, making reimbursement unlikely without a successful appeal. [8]

If you have employer-sponsored insurance, submit a coverage inquiry in writing before starting therapy. Request the specific formulary exclusion code. Some flexible spending accounts (FSAs) and health savings accounts (HSAs) do reimburse for compounded prescriptions when the compound is prescribed by a licensed physician for a diagnosable condition. [9] That route does not reduce the sticker price but does let you pay with pre-tax dollars, cutting the effective cost by your marginal tax rate.

Is Compounded Enclomiphene Citrate Legal in Louisiana?

Yes. Licensed 503A compounding pharmacies operating in Louisiana may legally compound enclomiphene citrate for individual patients when a valid prescription from a licensed prescriber exists. [10]

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. These pharmacies must be state-licensed, compound on a patient-specific basis, and not copy a commercially available FDA-approved drug. Because no approved enclomiphene product is on the market, the copying prohibition does not apply. [11] Louisiana's Board of Pharmacy enforces additional state-level standards covering beyond-use dating, sterility testing for applicable dosage forms, and pharmacist verification.

The FDA's 2022 guidance on compounded drug products reinforces that 503A pharmacies can compound drugs not on the FDA's Difficult-to-Compound list, and enclomiphene is not on that list. [12] Oral capsules and tablets, which are the standard enclomiphene dosage forms, fall well within 503A scope.

One important caveat: a 503B outsourcing facility may also supply enclomiphene to clinic dispensaries, but 503B facilities produce larger batches without patient-specific prescriptions. Whether your pharmacy is 503A or 503B affects how your prescription is handled but not your legal ability to receive the medication as a Louisiana patient.

The HealthRX prescribing framework for Louisiana patients seeking enclomiphene recommends confirming three things before dispensing: (1) the compounding pharmacy holds an active Louisiana Board of Pharmacy license, (2) a Certificate of Analysis (CoA) for the API batch is available on request, and (3) the prescriber has documented a morning total testosterone below 300 ng/dL on two separate draws, consistent with Endocrine Society diagnostic thresholds. [6]

Clinical Evidence Supporting Enclomiphene Use

Enclomiphene works by blocking estrogen receptors at the hypothalamus and pituitary, which increases gonadotropin-releasing hormone (GnRH) pulse frequency and drives LH and FSH secretion. That mechanism preserves the hypothalamic-pituitary-gonadal axis, unlike exogenous testosterone, which suppresses it. [13]

Kim et al. (BJU International, 2016) conducted a randomized controlled study of enclomiphene citrate versus testosterone gel in men with secondary hypogonadism. At 12 weeks, enclomiphene-treated men maintained sperm concentrations above baseline while testosterone-gel users experienced a mean 94% reduction in sperm concentration. Total testosterone normalized in both groups. [2] That sperm-preservation finding is clinically significant for men who want to maintain fertility while treating hypogonadism.

A phase 3 trial published in the Journal of Urology (Wiehle et al., 2014) enrolled 124 men with secondary hypogonadism. Enclomiphene 25 mg daily raised mean testosterone from 236 ng/dL to 439 ng/dL over 16 weeks (P<0.001 versus placebo). [14] LH and FSH both increased, confirming intact pituitary response.

The American Urological Association's 2018 guideline on male infertility recognizes clomiphene and its isomers as options for empiric treatment in men with secondary hypogonadism who desire fertility. [15] This guideline language is the closest to an authoritative endorsement available and is frequently cited in prior authorization letters.

Testosterone deficiency affects an estimated 2.1% to 3.7% of men overall, with prevalence rising to roughly 20% in men with type 2 diabetes. [16] Louisiana has one of the highest rates of type 2 diabetes in the United States at 13.4% of adults, which translates to a substantial local population who might qualify for enclomiphene therapy. [17]

Telehealth Access to Enclomiphene in Louisiana

Telehealth prescribing of enclomiphene is legal in Louisiana. A licensed physician or advanced practice registered nurse with Louisiana prescribing authority can evaluate a patient via synchronous video, order appropriate labs, and write a prescription for compounded enclomiphene without an in-person visit. [18]

Louisiana expanded its telehealth prescribing rules during and after the COVID-19 public health emergency. The Louisiana State Board of Medical Examiners now permits controlled substance and non-controlled substance prescribing via telemedicine when a valid prescriber-patient relationship is established. Enclomiphene is not a controlled substance, so the requirements are less stringent than for testosterone. [19]

Patients typically follow this sequence: schedule a telehealth visit with a men's health or endocrinology-focused provider, complete a morning blood draw at a local LabCorp or Quest Diagnostics site, share results with the provider, and receive an electronic prescription sent directly to a compounding pharmacy. Total time from inquiry to prescription is often three to seven days.

The practical advantage over in-person TRT clinics is cost. Many Louisiana TRT clinics charge $150 to $250 per in-person visit plus lab fees. Telehealth platforms frequently charge $75 to $150 for the initial consultation, with follow-ups at $50 to $75. Combined with the $90 pharmacy cost, a full month of enclomiphene therapy including the visit runs $140 to $240 in the first month and $140 to $165 in subsequent months. [20]

What Labs Are Required Before Prescribing in Louisiana?

Before a Louisiana provider writes an enclomiphene prescription, standard practice requires a specific set of baseline labs. These are not Louisiana-specific regulations but rather reflect Endocrine Society diagnostic standards and clinical prudence. [6]

Minimum required labs include: total testosterone (morning draw, two separate occasions), LH, FSH, prolactin, complete metabolic panel, and a complete blood count. Some providers also order estradiol (E2) at baseline because enclomiphene can raise estrogen through increased aromatization of the elevated testosterone it produces. [13]

A prolactin level matters because elevated prolactin (above 20 ng/mL in men) may indicate a pituitary adenoma, which changes the treatment plan entirely. [6] Sending a patient straight to enclomiphene without ruling out hyperprolactinemia is a prescribing error.

Follow-up labs at 6 and 12 weeks typically include total testosterone, LH, FSH, and hematocrit. Enclomiphene does not raise hematocrit the way exogenous testosterone does, but checking remains standard practice. [14] The lab costs in Louisiana at a cash-pay rate through LabCorp's patient pricing run approximately $60 to $90 for the full initial panel.

Discount Programs and Ways to Reduce Cost in Louisiana

Several options can reduce the effective monthly cost of enclomiphene for Louisiana patients paying cash.

GoodRx and similar discount card platforms list clomiphene citrate (the racemic mixture) but not enclomiphene specifically, because compounded drugs do not have NDC codes eligible for coupon processing. Discount cards therefore do not apply to compounded enclomiphene. [21]

HSA and FSA accounts remain the most accessible savings tool. A Louisiana resident in the 22% federal tax bracket who pays $90 per month via HSA saves roughly $238 annually compared to paying with after-tax dollars. [9]

Some telehealth platforms offer subscription pricing that bundles labs, visits, and the compounded medication into a fixed monthly fee ranging from $129 to $179. This can be cheaper than paying each component separately. Verify what the subscription includes before committing.

Patient assistance programs from the original Androxal developer (Repros Therapeutics) no longer operate because the NDA was never approved and the company ceased commercial operations. No manufacturer-backed copay card exists for enclomiphene as of 2026. [1]

Negotiating directly with the compounding pharmacy is an underused option. Pharmacies that dispense high volumes of compounded hormonal products sometimes offer a 10% to 15% discount for three-month prepayment. Ask explicitly; the discount is rarely advertised.

Side Effects and Monitoring Relevant to Louisiana Prescribers

Enclomiphene is generally well tolerated at 12.5 to 25 mg daily. The most commonly reported adverse effects in phase 3 trials were headache (9% vs. 5% placebo), nausea (7% vs. 4% placebo), and mood variability. [14] Visual disturbances, a class effect seen with clomiphene, occurred in fewer than 1% of enclomiphene subjects in published trials. [2]

Estradiol elevation deserves attention. Because enclomiphene raises endogenous testosterone, aromatization can push estradiol above the reference range (above 42.6 pg/mL in men on therapy). Elevated estradiol may cause gynecomastia or libido changes. [13] Louisiana prescribers managing this typically add anastrozole 0.5 mg twice weekly if E2 exceeds 50 pg/mL, although that adjustment itself is off-label. [6]

Men with a history of retinal vein occlusion, liver disease, or known hypersensitivity to clomiphene should not use enclomiphene. [11] The drug's structural similarity to clomiphene means the same contraindications carry over even in the absence of enclomiphene-specific labeling.

Louisiana does not have state-specific prescribing restrictions on SERMs for male hypogonadism beyond the standard federal requirements. Any licensed physician or APRN with appropriate prescribing authority can manage this therapy statewide. [19]

Enclomiphene Versus Testosterone Replacement in Louisiana: Cost Comparison

Exogenous testosterone therapy is cheaper in some formats. Testosterone cypionate 200 mg/mL (generic) runs approximately $30 to $45 per 10 mL vial at Louisiana retail pharmacies, which covers roughly 20 weeks of standard dosing at 100 mg per week. That translates to about $6 to $9 per month in drug cost alone. [22]

However, the monitoring burden is higher with TRT. Men on exogenous testosterone require hematocrit checks every three to six months, testicular volume monitoring, and sperm banking if fertility preservation matters. [15] The laboratory and clinic costs associated with responsible TRT monitoring add $40 to $100 per month, narrowing the cost gap.

Men who want to preserve fertility should not use exogenous testosterone. That single factor makes enclomiphene at $90 per month the lower-cost choice when fertility preservation is the goal, because the alternative would be concurrent use of human chorionic gonadotropin (hCG) alongside TRT, which adds $80 to $150 per month. [15]

For men with no fertility concerns, standard testosterone cypionate with appropriate monitoring remains the most cost-effective treatment for documented secondary hypogonadism in Louisiana.